公开(公告)号：US20230074381A1

公开(公告)日：2023-03-09

申请号：US17804934

申请日：2022-06-01

Applicant: UCB Biopharma SRL

Inventor： Helene Margaret Finney ,  Alastair David Griffiths Lawson ,  Stevan Graham Shaw ,  Bryan John Smith ,  Kerry Louise Tyson ,  Lara Kevorkian ,  Christoph Meier ,  Kaushik Sarkar ,  Paul Alan Atherfold

IPC: C07K16/28 ,  G01N33/50 ,  G01N33/564 ,  G01N33/68 ,  A61K47/60 ,  A61K47/64 ,  A61K39/395

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：US11746145B2

公开(公告)日：2023-09-05

申请号：US17136440

申请日：2020-12-29

Applicant: UCB BIOPHARMA SRL

Inventor： Kerry Louise Tyson ,  Terence Seward Baker ,  Georges Mairet-Coello ,  Patrick Downey ,  Jean-Philippe Courade ,  David Edward Ormonde Knight

IPC: C07K16/18 ,  C07K14/47 ,  A61P25/28 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61P25/28 ,  C07K14/4711 ,  G01N33/6896 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  G01N2333/4703 ,  G01N2800/28 ,  G01N2800/2821

Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.

公开(公告)号：US11261252B2

公开(公告)日：2022-03-01

申请号：US16513002

申请日：2019-07-16

Applicant: UCB BIOPHARMA SRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Michael John Wright ,  Kerry Louise Tyson

IPC: C07K16/28 ,  C07K16/18 ,  A61K39/00

Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.

公开(公告)号：US10906966B2

公开(公告)日：2021-02-02

申请号：US16458217

申请日：2019-07-01

Applicant: UCB BIOPHARMA SRL

Inventor： Kerry Louise Tyson ,  Terence Seward Baker ,  Georges Mairet-Coello ,  Patrick Downey ,  Jean-Philippe Courade ,  David Edward Ormonde Knight

IPC: C07K16/18 ,  C07K14/47 ,  A61P25/28 ,  G01N33/68 ,  A61K39/00

Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.

公开(公告)号：US11472879B2

公开(公告)日：2022-10-18

申请号：US16778523

申请日：2020-01-31

Applicant: UCB Biopharma SRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Kerry Louise Tyson ,  Michael John Wright

IPC: C07K16/28 ,  A01K67/027 ,  A61K39/00

Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

公开(公告)号：US11292831B2

公开(公告)日：2022-04-05

申请号：US16772043

申请日：2018-12-13

Applicant: UCB Biopharma SRL

Inventor： Patrick Downey ,  Kerry Louise Tyson ,  Marco Kriek ,  Lorenzo De Lichtervelde ,  Daniel John Lightwood ,  David James McMillan ,  Peter Charles Elliott ,  Terence Seward Baker

IPC: C07K16/18 ,  A61P25/16 ,  A61K39/00

Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

公开(公告)号：US11261242B2

公开(公告)日：2022-03-01

申请号：US16771993

申请日：2018-12-13

Applicant: UCB Biopharma SRL

Inventor： Ralph Adams ,  Patrick Downey ,  Terence Seward Baker ,  Kerry Louise Tyson ,  Lorenzo De Lichtervelde ,  Daniel John Lightwood ,  David James McMillan

IPC: C07K16/18 ,  A61K39/00

Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

公开(公告)号：US11518803B2

公开(公告)日：2022-12-06

申请号：US16925281

申请日：2020-07-09

Applicant: UCB BIOPHARMA SRL

Inventor： Helene Bon ,  Joanne Elizabeth Compson ,  Kate Louise Dixon ,  Carl Brendan Doyle ,  Mark Ellis ,  Maria Margarida Gouveia Sancho ,  Raymond Anthony Jupp ,  Lara Kevorkian ,  Daniel John Lightwood ,  Diane Marshall ,  Andrew Charles Payne ,  Joseph Michael David Rastrick ,  Monika-Sarah Schulze ,  Alison Turner ,  Kerry Louise Tyson

IPC: C07K16/22 ,  A61P11/00 ,  A61K9/00 ,  A61P11/12 ,  A61K39/395

Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.